Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPO receptor agonists for TKI-induced pancytopenia in CML patients in the Netherlands
NL-OMON58009Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of eltrombopag, romiplostim and avatrombopag in chronic myelogenous leukemia (CML), sponsored by Radboud University Medical Center. Primary endpoints: Hematological response to TPO-R agonists, Time to hematological recovery and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
eltrombopagromiplostimavatrombopag
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON58009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58009.